Advanced search
Publication Cover
Expert Opinion on Orphan Drugs Volume 4, 2016 - Issue 2
Submit an article Journal homepage
86
Views
1
CrossRef citations to date
0
Altmetric
Review

Managing seizures in mitochondrial disorders

Josef FinstererKrankenanstalt Rudolfstiftung, Vienna, AustriaCorrespondence[email protected]
&
Sinda Zarrouk-MahjoubGenomics Platform, Pasteur Institute of Tunis, Tunis, Tunisia
Pages 197-204 | Received 13 Oct 2015, Accepted 02 Dec 2015, Published online: 27 Dec 2015

References

•• Good overview about mitochondrial epilepsy.

• Good introduction to mitochondrial epilepsy.

  • Lax NZ, Grady J, Laude A, et al. Extensive respiratory chain defects in inhibitory interneurones in patients with mitochondrial disease. Neuropathol Appl Neurobiol. 2015 Mar 18. DOI:10.1111/nan.12238.
  • Finsterer J. Manifestations of the mitochondrial A3243G mutation. Int J Cardiol. 2009;137:60–62.
  • Demarest ST, Whitehead MT, Turnacioglu S, et al. Phenotypic analysis of epilepsy in the mitochondrial encephalomyopathy, lactic acidosis, and stroke like episodes-associated mitochondrial DNA A3243G mutation. J Child Neurol. 2014;29:1249–1256.
  • Kang HC, Lee YM, Kim HD. Mitochondrial disease and epilepsy. Brain Dev. 2013;35:757–761.
  • Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol. 2012;54:397–406.
  • Avula S, Parikh S, Demarest S, et al. Treatment of mitochondrial disorders. Curr Treat Options Neurol. 2014 Jun;16(6):292. DOI:10.1007/s11940-014-0292-7.
  • Burrage LC, Tang S, Wang J, et al. Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encodedATP6 gene. Mol Genet Metab. 2014;113:207–212.
  • Komulainen T, Lodge T, Hinttala R, et al. Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model. Toxicology. 2015;331:47–56.
  • Marmolino D, Manto M. Pregabalin antagonizes copper-induced toxicity in the brain: in vitro and in vivo studies. Neurosignals. 2010;18:210–222.
  • Finsterer J. Toxicitiy of antiepileptic drugs to mitochondria. In: Singh H, Sheu S-S, editors. Mitochondria. Handbook of experimental pharmacology. Elsevier; Forthcoming 2015.

•• Extenbsive overview about the toxic effects of AEDs to mitochondria.

  • Finsterer J, Zarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metabol Toxicol. 2012;9:71–79.
  • De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005;15:2315–2320.
  • Santos NA, Medina WS, Martins NM, et al. Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver. Toxicol In Vitro. 2008;22:1143–1152.
  • Hroudova J, Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31:336–342.
  • Araújo IM, Ambrósio AF, Leal EC, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia. 2004;45:1498–1505.
  • Goto M, Miyahara I, Hirotsu K, et al. Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin. J Biol Chem. 2005;280:37246–37256.
  • Luís PB, Ruiter JP, Aires CC, et al. Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation. Biochim Biophys Acta. 2007;1767:1126–1133.
  • Gilbert JC, Wyllie MG. Effects of anticonvulsant and convulsant drugs on the ATPase activities of synaptosomes and their components. Br J Pharmacol. 1976;56:49–57.
  • Riikonen R. The latest on infantile spasms. Curr Opin Neurol. 2005;18:91–95.
  • Lai JS, Zhao C, Warsh JJ, et al. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol. 2006;539:18–26.
  • Bachmann RF, Wang Y, Yuan P, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol. 2009;12:805–822.
  • Monti B, Gatta V, Piretti F, et al. Valproic acid is neuroprotective in the rotenone rat model of Parkinson’s disease: involvement of alpha-synuclein. Neurotox Res. 2010;17:130–141.
  • Bogdanov GN, Mishchenko DV, Kotelnikova RA, et al. Anticonvulsants as bioantioxidants under stress conditions. Biomed Khim. 2009;55:519–524.
  • Condello S, Currò M, Ferlazzo N, et al. Protective effects of zonisamide against rotenone-induced neurotoxicity. Neurochem Res. 2013;38:2631–2639.
  • Costa C, Tozzi A, Luchetti E, et al Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol. 2010;221:217–224.
  • Ueda Y, Doi T, Takaki M, et al Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res. 2009;1266:1–7.
  • Corda D, Rosati G, Deiana GA, et al. “Erratic” complex partial status epilepticus as a presenting feature of MELAS. Epilepsy Behav. 2006;8:655–658.
  • Kai T, Masuda S, Tokunaga H, et al. A case of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes(MELAS) with treatment-resistant status epilepticus that was effectively treated with lamotrigine. Rinsho Shinkeigaku. 2013;53:809–813.
  • Costello DJ, Sims KB. Efficacy of lamotrigine in disabling myoclonus in a patient with an mtDNA A3243G mutation. Neurology. 2009;72:1279–1280.
  • Desguerre I, Pinton F, Nabbout R, et al Infantile spasms with basal ganglia MRI hypersignal may reveal mitochondrial disorder due to T8993G MT DNA mutation. Neuropediatrics. 2003;34:265–269.
  • Letsas KP, Efremidis M, Pappas LK, et al. Pathophysiology and management of syncope in Kearns-Sayre syndrome. Am Heart Hosp J. 2006;4:301–302.
  • Kastrissianakis K, Anand G, Quaghebeur G, et al. Subdural effusions and lack of early pontocerebellar hypoplasia in siblings with RARS2 mutations. Arch Dis Child. 2013;98:1004–1007.
  • Emmanuele V, Silvers DS, Sotiriou E, et al. MERRF andKearns-Sayre overlap syndrome due to the mitochondrial DNA m.3291T>C mutation. Muscle Nerve. 2011;44:448–451.
  • Caietta E, Cano A, Halbert C, et al. Epilepsy and mitochondrial diseases: retrospective study on 53 epileptic children. Arch Pediatr. 2012;19:794–802.
  • Schinwelski M, Kierdaszuk B, Dulski J, et al. Changing phenotypic expression in a patient with a mitochondrial encephalopathy due to 13042G>A de novo mutation-a 5year follow up. Metab Brain Dis. 2015;30:1083–1085.
  • Ramaekers VT, Weis J, Sequeira JM, et al. Mitochondrial complex I encephalomyopathy and cerebral 5-methyltetrahydrofolate deficiency. Neuropediatrics. 2007;38:184–187.
  • Kim DY, Rho JM. The ketogenic diet and epilepsy. Curr Opin Clin Nutr Metab Care. 2008;11:113–120.
  • Allen BG, Bhatia SK, Buatti JM, et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013;19:3905–3913.
  • Steriade C, Andrade DM, Faghfoury H, et al. Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet. Pediatr Neurol. 2014;50:498–502.
  • Buda P, Piekutowska-Abramczuk D, Karkucińska-Więckowska A, et al. “Dropattacks” as first clinical symptoms in a child carrying MTTK m.8344A>G mutation. Folia Neuropathol. 2013;51:347–354.
  • Martikainen MH, Päivärinta M, Jääskeläinen S, et al. Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet. Epileptic Disord. 2012;14:438–441.
  • Spiegler J, Stefanova I, Hellenbroich Y, et al. Bowel obstruction inpatients with Alpers-Huttenlocher syndrome. Neuropediatrics. 2011;42:194–196.
  • Cardenas JF, Amato RS. Compound heterozygous polymerase gamma gene mutation in a patient with Alpers disease. Semin Pediatr Neurol. 2010;17:62–64.
  • Lee YM, Kang HC, Lee JS, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia. 2008;49:685–690.
  • Seo JH, Lee YM, Lee JS, et al. A case of Ohtahara syndrome with mitochondrial respiratory chain complex I deficiency. Brain Dev. 2010;32:253–257.
  • Kang HC, Kim HD, Lee YM, et al. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr Neurol. 2006;35:158–161.
  • Barnerias C, Saudubray JM, Touati G, et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol. 2010;52:e1–9.
  • Prasad C, Rupar T, Prasad AN. Pyruvate dehydrogenase deficiency and epilepsy. Brain Dev. 2011;33:856–865.
  • Azakli H, Gurses C, Arikan M, et al. Whole mitochondrial DNA variations in hippocampal surgical specimens and blood samples with high-throughput sequencing: a case of mesial temporal lobe epilepsy with hippocampal sclerosis. Gene. 2013;529:190–194.
  • Niehusmann P, Surges R, Von Wrede RD, et al. Mitochondrial dysfunction due to Leber’s hereditary optic neuropathy as a cause of visual loss during assessment for epilepsy surgery. Epilepsy Behav. 2011;20:38–43.
  • Conry JA. Pharmacologic treatment of the catastrophic epilepsies. Epilepsia. 2004;45(suppl 5):12–16.
  • Toribe Y, Tominaga K, Ogawa K, et al. Usefulness of L-arginine infusion for status epilepticus in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. No To Hattatsu. 2007;39:38–43.
  • Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of stroke like episodes in MELAS. Neurology. 2005;64:710–712.
  • Prüss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82:219–222.
  • Koga Y, Povalko N, Katayama K, et al. Beneficial effect of pyruvate therapy on Leigh syndrome due to a nov mutation in PDH E1α gene. Brain Dev. 2012;34:87–91.
  • Simeone KA, Matthews SA, Samson KK, et al. Targeting deficiencies in mitochondrial respiratory complex I and functional uncoupling exerts anti-seizure effects in a genetic model of temporal lobe epilepsy and in a model of acute temporal lobe seizures. Exp Neurol. 2014;251:84–90.
  • Windpessl M, Müller P. Valproic acid and MELAS: a word of warning. Intern Med. 2013;52:1011.
  • Tsao CY. Cerebellar ataxia, vertical supranuclear gaze palsy, sensorineural deafness, epilepsy, dementia, and hallucinations in an adolescent male. Semin Pediatr Neurol. 2014;21:106–108.
  • Sproule DM, Dyme J, Coku J, et al. Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA((Leu)) gene (m.3243A>G). J Inherit Metab Dis. 2008;31(suppl 3):497–503.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.